

3 July 2024

## Treatment of inflammatory diseases

I would be grateful if you could tell me how many patients were treated by individual drug for Crohn's Disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis in three months from the start of Jan 2024 to the end of Mar 2024 (or the latest available 3 months).

I have provided a grid of drug names and disease names requested (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation.

The table below outlines Belfast Trust's response.

### Note:

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

3 July 2024

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab (Humira)	24	25	5	132	65	57
Adalimumab (Biosimilars)	194	300	100	243	147	148
Apremilast				19		
Bimekizumab	12			11	<5	
Brodalumab	<5					
Certolizumab Pegol	8			55	21	25
Deucravacitinib	<5					
Etanercept (Enbrel)	<5			25	15	28
Etanercept (Biosimilars)	5			109	55	83
Guselkumab	89					
Infliximab (Remicade)	<5	20	20	15	10	<5
Infliximab (Biosimilars)	<5	200	200	12	10	<5
Ixekizumab	61			74	22	
Risankizumab	93	6		<5		
Secukinumab	39			148	51	
Tildrakizumab	5					
Ustekinumab	70	180	5	8		
Upadacitinib		15	5	15	11	23
Vedolizumab		110	160			
Filgotinib			10			<5
Golimumab			5	49	23	6
Mirikizumab			0			
Ozanimod			2			
Tofacitinib			10	5	<5	<5
Baricitinib						18
Rituximab						16
Sarilumab						<5
Tocilizumab						63